Eric Schmidt Analyst PerformanceAnalyst at Cantor FitzgeraldEric Schmidt is a stock analyst at Cantor Fitzgerald focused in the medical sector, covering 26 publicly traded companies. Over the past year, Eric Schmidt has issued 14 stock ratings, including strong buy, buy, and hold recommendations. While full access to Eric Schmidt's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Eric Schmidt's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings94 Last 10 YearsBuy Recommendations85.11% 80 Buy RatingsCompanies Covered26 Unique Companies Ratings Distribution94RatingsDistribution of strong buy, buy, hold, and sell ratings by Eric Schmidt.RatingPercentageCount Strong Buy1.1%1 ratings Buy84.0%79 ratings Hold14.9%14 ratings Sell0.0%0 ratingsOut of 94 total stock ratings issued by Eric Schmidt at Cantor Fitzgerald, the majority (84.0%) have been Buy recommendations, followed by 14.9% Hold and 1.1% Strong Buy.Best & Worst CallsBest Call000000.0%CDTXJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%RGLSJun 2016Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ88.5% of companies on NASDAQ23 companiesNYSE11.5% of companies on NYSE3 companiesEric Schmidt, an analyst at Cantor Fitzgerald, currently covers 26 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical25 companies96.2%Manufacturing1 company3.8%Eric Schmidt of Cantor Fitzgerald specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE21 companies80.8%MED - DRUGS3 companies11.5%Miscellaneous1 company3.8%PHARMACEUTICAL PREPARATIONS1 company3.8% Eric Schmidt's Ratings History at Cantor Fitzgerald Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsACLXArcellx4/29/2026Reiterated Rating$115.07Neutral$0.0000.00% ROIGENBGenerate Biomedicines3/24/2026Initiated Coverage$12.52Overweight$0.0000.00% ROILEGNLegend Biotech12/17/2025Lower Price Target$21.65$74.00Overweight$0.0000.00% ROISRRKScholar Rock12/11/2025Reiterated Rating$45.75Overweight$0.0000.00% ROILEGNLegend Biotech11/13/2025Boost Price Target$31.31$75.00Overweight$0.0000.00% ROIVSTMVerastem10/30/2025Upgrade$9.23Strong-Buy$0.0000.00% ROIVSTMVerastem10/16/2025Initiated Coverage$9.77Overweight$0.0000.00% ROIACLXArcellx10/9/2025Reiterated Rating$88.29$88.00Neutral$0.0000.00% ROIACLXArcellx10/9/2025Downgrade$88.39$88.00Hold$0.0000.00% ROILEGNLegend Biotech10/7/2025Initiated Coverage$31.44$40.00Overweight$0.0000.00% ROISMMTSummit Therapeutics9/8/2025Reiterated Rating$22.00Overweight$0.0000.00% ROILEGNLegend Biotech8/27/2025Reiterated Rating$35.08$66.00Overweight$0.0000.00% ROISRRKScholar Rock7/17/2025Initiated Coverage$41.15Overweight$0.0000.00% ROIRNAAvidity Biosciences6/27/2025Reiterated Rating$29.83$96.00Overweight$0.0000.00% ROIIMTXImmatics4/1/2025Reiterated Rating$4.23Overweight$0.0000.00% ROIGLYCGlycoMimetics3/21/2025Initiated Coverage$0.27Overweight$0.0000.00% ROISMMTSummit Therapeutics3/21/2025Initiated Coverage$19.44Overweight$00.0000.00% ROIALMSAlumis3/20/2025Reiterated Rating$4.33Overweight$00.0000.00% ROIADCTADC Therapeutics3/7/2025Reiterated Rating$1.84Overweight$0.0000.00% ROIPRTAProthena2/21/2025Reiterated Rating$15.78Overweight$0.0000.00% ROICRSPCRISPR Therapeutics2/19/2025Reiterated Rating$53.38Neutral$00.0000.00% ROICDTXCidara Therapeutics1/27/2025Reiterated Rating$19.51Overweight$000.0000.00% ROIINCYIncyte1/10/2025Reiterated Rating$70.17Neutral$000.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenMorgan StanleyRoyal Bank Of CanadaBerenberg BankUBS GroupCitigroupBarclaysWells Fargo & CompanyJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James Financial Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
